Quince Therapeutics, Inc. Logo

Quince Therapeutics, Inc.

Late-stage biotech developing red blood cell-encapsulated drugs for rare diseases.

QNCX | US

Overview

Corporate Details

ISIN(s):
US22053A1079
LEI:
Country:
United States of America
Address:
611 GATEWAY BLVD., SUITE 273, 94080 SOUTH SAN FRANCISCO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Quince Therapeutics, Inc. is a late-stage biotechnology company focused on developing and commercializing therapeutics for rare diseases. The company's core technology is its proprietary Autologous Intracellular Drug Encapsulation (AIDE) platform, a novel drug/device combination that encapsulates drugs within a patient's own red blood cells. This delivery system is designed to improve tolerability, enhance tissue biodistribution, and reduce the adverse effects of potent medicines. Quince's lead product candidate, eDSP, is in a pivotal Phase 3 clinical trial for the treatment of Ataxia-Telangiectasia (A-T), a rare pediatric neurodegenerative disease with no currently approved therapies. The eDSP System has received Fast Track designation from the U.S. Food and Drug Administration.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Quince Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Quince Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Quince Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
GREEN CROSS WellBeing Corporation Logo
Develops personalized nutrition solutions, from prescription injections to supplements & cosmetics.
South Korea 234690
Greenwich LifeSciences, Inc. Logo
Developing an immunotherapy vaccine to prevent recurrence in HER2-positive breast cancer patients.
United States of America GLSI
GRI Bio, Inc. Logo
Advancing NKT cell modulators for inflammatory, fibrotic, and autoimmune diseases.
United States of America GRI
Grifols S.A. Logo
Leading producer of plasma-derived medicines for patients with rare and chronic diseases.
Spain GRF
Grindeks Logo
Develops & manufactures pharmaceuticals for cardiovascular, CNS, cancer, and diabetes globally.
Latvia GRD1R
GT Biopharma, Inc. Logo
Develops TriKE® immunotherapies engaging NK cells to treat hematologic and solid tumor cancers.
United States of America GTBP
Guardant Health, Inc. Logo
Develops liquid biopsies for cancer detection, monitoring, and personalized treatment guidance.
United States of America GH
Guard Therapeutics International AB Logo
Clinical-stage biotech developing drugs to prevent acute kidney injury during open-heart surgery.
Sweden GUARD
Develops research antibodies and distributes scientific instruments for life science researchers.
South Korea 036180
GYRE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing novel drugs for liver fibrosis and pneumoconiosis.
United States of America GYRE

Talk to a Data Expert

Have a question? We'll get back to you promptly.